Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patie...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-06-01
|
| Series: | Prostate International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S228788821530026X |
| _version_ | 1797763930699857920 |
|---|---|
| author | Yasuhide Kitagawa Atsushi Mizokami Mikio Namiki |
| author_facet | Yasuhide Kitagawa Atsushi Mizokami Mikio Namiki |
| author_sort | Yasuhide Kitagawa |
| collection | DOAJ |
| description | Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patients aged 55 to 69 years old in our institution.
Methods: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with systemic symptoms. We analyzed the clinical courses of the patients in each group.
Results: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups.
Conclusions: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have better prognosis than those with symptoms. |
| first_indexed | 2024-03-12T19:49:24Z |
| format | Article |
| id | doaj.art-b0415ef9eb754ac5b6863e311fd8cf13 |
| institution | Directory Open Access Journal |
| issn | 2287-8882 |
| language | English |
| last_indexed | 2024-03-12T19:49:24Z |
| publishDate | 2013-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Prostate International |
| spelling | doaj.art-b0415ef9eb754ac5b6863e311fd8cf132023-08-02T03:20:14ZengElsevierProstate International2287-88822013-06-0112656810.12954/PI.12017Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screeningYasuhide KitagawaAtsushi MizokamiMikio NamikiDue to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patients aged 55 to 69 years old in our institution. Methods: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with systemic symptoms. We analyzed the clinical courses of the patients in each group. Results: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups. Conclusions: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have better prognosis than those with symptoms.http://www.sciencedirect.com/science/article/pii/S228788821530026XProstate neoplasmsClinical symptomsProstate-specific antigen screeningPrognosis |
| spellingShingle | Yasuhide Kitagawa Atsushi Mizokami Mikio Namiki Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening Prostate International Prostate neoplasms Clinical symptoms Prostate-specific antigen screening Prognosis |
| title | Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening |
| title_full | Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening |
| title_fullStr | Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening |
| title_full_unstemmed | Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening |
| title_short | Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening |
| title_sort | trends of clinical symptoms and prognosis of middle aged prostate cancer patients after instigation of prostate specific antigen based population screening |
| topic | Prostate neoplasms Clinical symptoms Prostate-specific antigen screening Prognosis |
| url | http://www.sciencedirect.com/science/article/pii/S228788821530026X |
| work_keys_str_mv | AT yasuhidekitagawa trendsofclinicalsymptomsandprognosisofmiddleagedprostatecancerpatientsafterinstigationofprostatespecificantigenbasedpopulationscreening AT atsushimizokami trendsofclinicalsymptomsandprognosisofmiddleagedprostatecancerpatientsafterinstigationofprostatespecificantigenbasedpopulationscreening AT mikionamiki trendsofclinicalsymptomsandprognosisofmiddleagedprostatecancerpatientsafterinstigationofprostatespecificantigenbasedpopulationscreening |